Immunophenotype of normal and myelomatous plasma-cell subsets

Area of Science:

• Immunology
• Hematology
• Oncology

Background:

• Plasma cells (PCs) are terminally differentiated B-cells crucial for antibody production.
• PCs are typically identified by CD138 and CD38 co-expression via flow cytometry.
• Malignant PCs in multiple myeloma (MM) can display altered marker expression and accumulate in bone marrow.

Purpose of the Study:

• To investigate the immunophenotypic heterogeneity of plasma cells in normal and multiple myeloma bone marrow.
• To explore the expression of various surface markers, including CD19, CD28, CD33, CD56, CD117, CD20, and CD27, on plasma cells.
• To correlate plasma cell immunophenotypes with potential therapeutic implications in multiple myeloma.

Main Methods:

• Flow cytometry analysis of bone marrow samples from normal individuals and MM patients.
• Characterization of plasma cell subsets based on CD19, CD56, and CD28 expression.
• Investigation of aberrant marker expression (CD20, CD27, CD33, CD56, CD117) on malignant plasma cells.

Main Results:

• Normal and malignant plasma cells exhibit distinct immunophenotypic profiles.
• Malignant plasma cells in MM show significant heterogeneity in marker expression, including gain or loss of specific markers like CD27, CD20, CD28, CD33, CD56, and CD117.
• Plasma cells display isotypic restriction, with clonal malignant PCs expressing either kappa or lambda light chains, often forming an abnormal peak in serum protein electrophoresis.

Conclusions:

• The immunophenotype of plasma cells is highly heterogeneous, particularly in multiple myeloma.
• This heterogeneity in plasma cell markers may contribute to the varied responses observed in multiple myeloma patients undergoing therapy.
• Further characterization of plasma cell immunophenotypes is essential for understanding MM pathogenesis and optimizing treatment strategies.